Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07003984 · ClinicalTrials.gov registry record · Phase 3
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
A Phase 3 study of Chikungunya Virus, sponsored by Bavarian Nordic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
- 9
- Study locations
NCT07003984: Recruiting Phase 3 study of Chikungunya Virus, sponsored by Bavarian Nordic.
NCT07003984 is a Phase 3 study of Chikungunya Virus that is actively recruiting participants, run by Bavarian Nordic. The registered enrollment target is 720 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07003984, a Phase 3 study of Chikungunya Virus, is actively recruiting participants, sponsored by Bavarian Nordic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to \<12 years of age.
Primary Outcome
Incidence of adverse events of special interest (AESIs; defined as new onset or worsening arthralgia that is medically attended), medically attended adverse events (MAAEs), and serious adverse events (SAEs) through end of the trial.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CHIKV VLP vaccine
Study Locations (9)
Florida
- Acevedo Clinical Research - Miami
- Hope Research Network - Miami
California
- ARK Clinical Research, LLC - Fountain Valley
District of Columbia
- Emerson Clinical Research Institute- DC - Washington D.C.
Nebraska
- Velocity Clinical Research-Omaha - Omaha
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Texas
- KidCare Pediatrics - Beaumont
Utah
- Velocity Clinical Research - Salt Lake City - West Jordan
Puerto Rico
- Caribbean Medicine Center - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT07003984 shows while recruiting
NCT07003984 is an interventional study that assigns participants to a tested intervention. The registered 720 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Chikungunya Virus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07003984 lists 9 locations in 8 states (Florida, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT07003984 about?
NCT07003984 is a clinical study titled "A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.". The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to \<12 years of age.
What is the current status of trial NCT07003984?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2025-06-05. Estimated completion is 2028-12.
What conditions does trial NCT07003984 study?
This clinical trial studies the following conditions: Chikungunya Virus.
What interventions are being tested in trial NCT07003984?
The interventions under investigation include: Placebo (BIOLOGICAL), CHIKV VLP vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07003984?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07003984 being conducted?
This trial has 9 study locations across California, District of Columbia, Florida, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chikungunya Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07003984's enrollment target sits among peer trials
720 494th of 2000 higher than 1,504 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
- NCT05466214 · 720 participants · NA
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI